Apomorphine - Research News and Information

Thursday, January 08, 2009

Safety and efficacy of an ocular insert for apomorphine-induced emesis in dogs.

29 Sep 2008 OBJECTIVE: To evaluate the safety and efficacy of an ocular insert designed to provide controlled release of apomorphine for the induction of emesis in dogs. ANIMALS: 5,001 dogs treated with ocular apomorphine inserts and 32 dogs treated with IV ... Read more...

Dopamine D5 receptors: a challenge to medicinal chemists.

30 Aug 2008 Due to the lack of highly selective dopamine D(1) or D(5) receptor ligands, only few data about activation or blocking of these receptor subtypes are available. The present review collects the available information about molecules with notable ... Read more...

Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret.

13 Jul 2008 The chemotherapeutic drug cisplatin is associated with severe gastrointestinal toxicity that can last for several days. A recent strategy to treat the nausea and emesis includes the combination of a 5-HT3 receptor antagonist, a glucocorticoid, and ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Apomorphine'

These are the very latest articles for this heading:

• Safety and efficacy of an ocular insert for apomorphine-induced emesis in dogs. 29 Sep 2008
• Dopamine D5 receptors: a challenge to medicinal chemists. 30 Aug 2008
• Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret. 13 Jul 2008
• Acute Akinesia, an unusual complication in Parkinson's Disease: a case report. 7 Jul 2008
• Effects of white and infrared lighting on apomorphine-induced pecking in pigeons. 29 Jun 2008
• Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. 18 Jun 2008
• Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. 13 Jun 2008
• Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. 2 Jun 2008
• Induction of tolerance of dopaminergic responses in man. 26 May 2008
• The CRF-like peptide urocortin produces a long-lasting recovery in rats made hemiparkinsonian by 6-hydroxydopamine or lipopolysaccharide. 25 May 2008
• 5-HT(2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats. 22 May 2008
• Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. 19 May 2008
• Lack of persistent effects of ketamine in rodent models of depression. 5 May 2008
• Commentary on apomorphine versus sildenafil for erectile dysfunction. 29 Apr 2008
• Characterization of functional roles of DRY motif in the 2nd intracellular loop of dopamine D2 and D3 receptors. 29 Apr 2008
• Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. 29 Apr 2008
• [Experimental study of the effects of citalopram, olanzapine, and their combinations in tests for antipsychotic, antidepressant and anxiolytic activities of drugs] 29 Apr 2008
• [Effect of apomorphine injection into the nucleus accumbens on the limb preference in manipulation movements in rats] 29 Apr 2008
• Modulation of horizontal cell function by dopaminergic ligands in mammalian retina. 26 Apr 2008
• Preferential relocation of the N-methyl-D-aspartate receptor NR1 subunit in nucleus accumbens neurons that contain dopamine D1 receptors in rats showing an apomorphine-induced sensorimotor gating deficit. 10 Apr 2008

See a longer list of these articles.

Technical information about 'Apomorphine'

Definition: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.

Chemical name: 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)-

Registry Number: 58-00-4

Descriptor UI: D001058

Alternative terms: Apomorphine; Apomorphine Hydrochloride, Anhydrous; Anhydrous Apomorphine Hydrochloride; Hydrochloride, Anhydrous Apomorphine; Apomorphine Hydrochloride, Hemihydrate; Hemihydrate Apomorphine Hydrochloride; Hydrochloride, Hemihydrate Apomorphine; Apomorphin-Teclapharm; Apomorphin Teclapharm; ApomorphinTeclapharm; Teclapharm Brand of Apomorphine Hydrochloride; Apokinon; Aguettant Brand of Apomorphine Hydrochloride; Apomorphine Chloride; Chloride, Apomorphine; Britaject; Britannia Brand of Apomorphine Hydrochloride;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiparkinson Agents; Dopamine Agonists;

Tree Number: D03.132.098.038.290; D03.438.531.085.030.290; D03.549.095.290;

Online Note: use APOMORPHINE/analogs & derivatives to search APOMORPHINE DERIVATIVES 1975-77; use APOMORPHINE 1969-74

History Note: APOMORPHINE DERIVATIVES was see under APOMORPHINE 1969-77

Technical Notes: apomorphine derivatives = APOMORPHINE/analogs